Immuneering (IMRX) Operating Margin: 2020-2022
Historic Operating Margin for Immuneering (IMRX) over the last 3 years, with Dec 2022 value amounting to -3,073,627.91%.
- Immuneering's Operating Margin fell 306776489.00% to -3,073,627.91% in Q4 2022 from the same period last year, while for Dec 2022 it was -16,325.77%, marking a year-over-year decrease of 1469661.00%. This contributed to the annual value of -16,325.77% for FY2022, which is 1469661.00% down from last year.
- According to the latest figures from Q4 2022, Immuneering's Operating Margin is -3,073,627.91%, which was down 8,844.84% from -34,362.04% recorded in Q3 2022.
- Immuneering's Operating Margin's 5-year high stood at -644.66% during Q3 2020, with a 5-year trough of -3,073,627.91% in Q4 2022.
- In the last 3 years, Immuneering's Operating Margin had a median value of -1,772.01% in 2021 and averaged -285,384.79%.
- Data for Immuneering's Operating Margin shows a maximum YoY plummeted of 306,776,489bps (in 2022) over the last 5 years.
- Immuneering's Operating Margin (Quarterly) stood at -877.56% in 2020, then plummeted by 498,546bps to -5,863.02% in 2021, then tumbled by 306,776,489bps to -3,073,627.91% in 2022.
- Its last three reported values are -3,073,627.91% in Q4 2022, -34,362.04% for Q3 2022, and -12,334.43% during Q2 2022.